Table 5.

Clinical characteristics, follow-up, and outcomes of EXT1/EXT2-positive and EXT1/EXT2-negative LMN without proliferative features (pure class 5)

VariableEXT1/EXT2-Positive LMN, n=48/64 (75.0%)EXT1/EXT2-Negative LMN, n=65/96 (67.7%)P Valuea
Age at presentation, median (IQR), yr33 (25–42)40 (28–47)0.12
Female, n (%)42 (87.5)53 (81.5)0.39
SCr at presentation, median (IQR), mg/dl0.70 (0.60–0.90), n=460.80 (0.60–1.30), n=580.01
Proteinuria at presentation, median (IQR), g/24 h3.5 (1.5–5.9), n=402.8 (1.40–4.3), n=510.23
Proteinuria at presentation ≥3.5/d, n (%)23 (57.5), n=4018 (35.3), n=510.04
Hematuria, n (%)15 (31.3)22 (33.8)0.77
Other autoimmune diseases, n (%)14 (29.2)15 (23.1)0.46
Sclerosed glomeruli, median (IQR), %0.0 (0.0–8.5)9.5 (0.0–24.4)<0.001
IFTA, median (IQR), %0.0 (0.0–0.0)10.0 (5.0–25.0)<0.001
SCr at end of follow-up, median (IQR), mg/dl0.85 (0.70–1.13), n=381.00 (0.70–1.57), n=510.09
Proteinuria at end of follow-up, median (IQR), g/24 h0.95 (0.20–2.55), n=260.90 (0.20–1.93), n=420.46
Proteinuria at end of follow-up ≥3.5/d, n (%)3 (11.5), n=266 (14.3), n=420.75
ESKD, n (%)2 (4.2)11 (16.9)0.04
Death, n (%)2 (4.2)2 (3.1)0.76
Time of follow-up, median (IQR), mo52.5 (31.6–81.2)53.6 (34.2–97.1)0.61
  • a P<0.05 is considered significant.